Elan wins shareholder approval to complete Perrigo sale
DUBLIN (Reuters) - Ireland's Elan won approval from shareholders on Monday to complete the sale of the company to U.S. drugmaker Perrigo, clearing the way for the deal to be completed by the end of the year.
Perrigo agreed to buy the Dublin-based group for $8.6 billion in July in a deal that will hand it tax savings from being domiciled in Ireland and royalties from blockbuster multiple sclerosis treatment Tysabri.
The deal ended a bitter takeover battle in which Elan rejected three lower bids from U.S. investment firm Royalty Pharma.
(Reporting by Padraic Halpin; editing by Keiron Henderson)
- Israel strikes house of Hamas Gaza leader, digs in for long fight |
- West agrees wider Russia sanctions as Kiev says forces near crash site |
- U.S. says Russia violated nuclear treaty, urges immediate talks
- Judge gives go-ahead for $2 billion sale of NBA's Clippers
- Jaded Argentines brace for looming debt default